Today marks #EUFluDay , a dedicated awareness day highlighting the critical role of vaccination in protecting vulnerable populations against respiratory illnesses like influenza. This year, the focus is on achieving the EU's target of vaccinating 75% of vulnerable individuals against the flu. Despite this goal, only 51% of older adults were vaccinated in 2021, underscoring the urgent need for increased efforts. In addition, this awareness day emphasizes expanding the vaccination target to include COVID-19 and RSV, recognizing their importance for public health. As we enter the flu season in the Northern Hemisphere, it is crucial to remember the serious impact flu can have on our communities. #EUImmunisationStrategy #TogetherAgainstFlu #FluVaccination #EU4Health #StrongerTogether
CSL's 2024 R&D Investor Briefing
Webcast will be live from 9am on Tuesday, 22nd October 2024 (AEDT).
We have released our 2024 Annual Report Click here to read the Annual Report → | We have announced our 2024 Full Year Financial Results for the period ending June 30th 2024. Click here to view Information and Webcast Recording →
CSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and ProductsCSL. Always Evolving for a Better World.
CSL has delivered biotechnology excellence for over a century. Today, with the combined expertise of CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, CSL’s offerings are more diverse than ever to help ensure patients and people everywhere get the treatments they need. We’re always improving so life can, too.
Our Businesses and ProductsCSL Behring. Leading the Way in Treating Rare and Serious Diseases.
CSL Behring is a global biotech leader with a broad range of biotherapies for rare and serious diseases including bleeding disorders, immunodeficiencies, hereditary angioedema, neurological disorders and Alpha 1 Antitrypsin Deficiency.
More About CSL BehringCSL Seqirus. Global Vaccine Leader.
Through the power of innovation, our vision is to advance science to enhance public health worldwide. We stand on the front line with partners in public health discovering, developing, and delivering pioneering vaccine solutions to safeguard people and communities across the world.
More About CSL SeqirusCSL Vifor. Changing the Game in Iron Deficiency and Nephrology.
The newest member of the CSL family, CSL Vifor is a global leader in iron deficiency and nephrology and is committed to launching the next generation of therapies to truly address the full spectrum of kidney disease, with a focus on dialysis and rare disease.
More About CSL ViforVita: Original Stories
'Vita' means life. It's also where we share the stories of biotech's promise to patients and public health.
Careers at CSL
We are committed to helping employees fulfill their career aspirations while working in a values-based culture. Are you next?
Pictured: CSL employees in Melbourne, Australia